VR Adviser’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

VR Adviser’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,770,705	Closed	-$7.05M	–	30
2022 Q4	$7.05M	Sell	1,770,705 -1,386,098	-44%	-$6.81M	1.19%	21
2022 Q3	$21M	Hold	3,156,803	–	–	3.24%	10
2022 Q2	$15.3M	Hold	3,156,803	–	–	3.01%	11
2022 Q1	$29.5M	Buy	3,156,803 +276,707	+10%	+$2.75M	4.78%	8
2021 Q4	$34.2M	Buy	2,880,096 +238,287	+9%	+$2.75M	4.68%	8
2021 Q3	$30.1M	Hold	2,641,809	–	–	3.86%	12
2021 Q2	$47.4M	Hold	2,641,809	–	–	5.75%	5
2021 Q1	$40.9M	Buy	2,641,809 +52,868	+2%	+$765K	4.44%	9
2020 Q4	$31.6M	Buy	2,588,941 +1,396,058	+117%	+$19.5M	4.64%	8
2020 Q3	$15.3M	Sell	1,192,883 -238,752	-17%	-$2.06M	3%	12
2020 Q2	$14.5M	Sell	1,431,635 -194,075	-12%	-$1.79M	3.48%	9
2020 Q1	$13.2M	Buy	+1,625,710	New	+$14.1M	3.58%	9

Other funds holding MRNS

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

VR Adviser's MRNS Position: Q1 2023 in Review

VR Adviser sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2023, closing a stake of 1,770,705 shares — an estimated $7.05M sold.

VR Adviser first reported a position in MRNS in Q1 2020 and held it in 12 quarters. The position peaked at $47.4M in Q2 2021. 86 funds tracked by Wall St. Rank hold MRNS as of Q1 2023.

VR Adviser reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
VR Adviser sold 1,770,705 Marinus Pharmaceuticals, Inc shares in Q1 2023, an estimated $7.05M.
VR Adviser first reported a position in Marinus Pharmaceuticals, Inc in Q1 2020 and held it in 12 quarters.
VR Adviser's Marinus Pharmaceuticals, Inc position peaked at $47.4M in Q2 2021.
86 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2023.

Based on VR Adviser's 13F filing for Q1 2023, filed 15 May 2023.